233 related articles for article (PubMed ID: 29032719)
1. Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, Canada.
Lee LJ; Toze CL; Huang SJT; Gillan TL; Connors JM; Sehn LH; Bruyere H; Leitch H; Ramadan KM; Gerrie AS
Leuk Lymphoma; 2018 Jun; 59(6):1356-1363. PubMed ID: 29032719
[TBL] [Abstract][Full Text] [Related]
2. Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada.
Huang SJ; Gerrie AS; Young S; Tucker T; Bruyere H; Hrynchak M; Galbraith P; Al Tourah AJ; Dueck G; Noble MC; Ramadan KM; Tsang P; Hardy E; Sehn L; Toze CL
Leuk Res; 2020 Apr; 91():106335. PubMed ID: 32114372
[TBL] [Abstract][Full Text] [Related]
3. Impact of age and treatment institution type on outcomes of patients treated for chronic lymphocytic leukemia in British Columbia, Canada.
Huang SJ; Gerrie AS; Young S; Tucker T; Bruyère H; Hrynchak M; Galbraith P; Al Tourah AJ; Dueck G; Noble MC; Ramadan KM; Tsang P; Hardy E; Sehn LH; Toze CL
Leuk Res; 2021 Apr; 103():106538. PubMed ID: 33647819
[TBL] [Abstract][Full Text] [Related]
4. Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: population-based experience matches clinical trials.
Gerrie AS; Toze CL; Ramadan KM; Li CH; Sutherland J; Yee A; Connors JM
Leuk Lymphoma; 2012 Jan; 53(1):77-82. PubMed ID: 21756026
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in combination with chemotherapy for the treatment of chronic lymphocytic leukaemia in clinical practice.
Reiser M; Dörfel S; Hensel M; Hoesl M; Jordan WO; Koenigsmann M; Meyer D; Reichert D; Schwarzer A; Marquardt M; Kellershohn K; Jentsch-Ullrich K
Eur J Haematol; 2018 May; 100(5):455-464. PubMed ID: 29393986
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.
Herishanu Y; Goldschmidt N; Bairey O; Ruchlemer R; Fineman R; Rahimi-Levene N; Shvidel L; Tadmor T; Ariel A; Braester A; Shapiro M; Joffe E; Polliack A;
Haematologica; 2015 May; 100(5):662-9. PubMed ID: 25661442
[TBL] [Abstract][Full Text] [Related]
7. Characterization of treatment and outcomes in a population-based cohort of patients with chronic lymphocytic leukemia referred for cytogenetic testing in British Columbia, Canada.
Huang SJ; Lee LJ; Gerrie AS; Gillan TL; Bruyere H; Hrynchak M; Smith AC; Karsan A; Ramadan KM; Jayasundara KS; Toze CL
Leuk Res; 2017 Apr; 55():79-90. PubMed ID: 28157628
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity.
Thompson PA; Stingo F; Keating MJ; Ferrajoli A; Burger JA; Wierda WG; Kadia TM; O'Brien SM
Cancer; 2016 Aug; 122(16):2505-11. PubMed ID: 27182988
[TBL] [Abstract][Full Text] [Related]
9. Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China.
Li Z; Li F; Yi S; Gu Z; Yu Z; Xu Y; Feng X; Liu W; Zou D; Qi J; Zhan F; Qiu L
BMC Cancer; 2015 Jul; 15():555. PubMed ID: 26219471
[TBL] [Abstract][Full Text] [Related]
10. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
Greil R; Obrtlíková P; Smolej L; Kozák T; Steurer M; Andel J; Burgstaller S; Mikušková E; Gercheva L; Nösslinger T; Papajík T; Ladická M; Girschikofsky M; Hrubiško M; Jäger U; Fridrik M; Pecherstorfer M; Králiková E; Burcoveanu C; Spasov E; Petzer A; Mihaylov G; Raynov J; Oexle H; Zabernigg A; Flochová E; Palášthy S; Stehlíková O; Doubek M; Altenhofer P; Pleyer L; Melchardt T; Klingler A; Mayer J; Egle A
Lancet Haematol; 2016 Jul; 3(7):e317-29. PubMed ID: 27374465
[TBL] [Abstract][Full Text] [Related]
11. Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States.
Nabhan C; Mato A; Flowers CR; Grinblatt DL; Lamanna N; Weiss MA; Davids MS; Swern AS; Bhushan S; Sullivan K; Flick ED; Kiselev P; Sharman JP
BMC Cancer; 2017 Mar; 17(1):198. PubMed ID: 28302090
[TBL] [Abstract][Full Text] [Related]
12. A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor.
Rogers KA; Huang Y; Ruppert AS; Salem G; Stephens DM; Heerema NA; Andritsos LA; Awan FT; Byrd JC; Flynn JM; Maddocks KJ; Jones JA
Br J Haematol; 2018 Jan; 180(2):259-266. PubMed ID: 29193006
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.
Cuneo A; Follows G; Rigolin GM; Piciocchi A; Tedeschi A; Trentin L; Perez AM; Coscia M; Laurenti L; Musuraca G; Farina L; Delgado AR; Orlandi EM; Galieni P; Mauro FR; Visco C; Amendola A; Billio A; Marasca R; Chiarenza A; Meneghini V; Ilariucci F; Marchetti M; Molica S; Re F; Gaidano G; Gonzalez M; Forconi F; Ciolli S; Cortelezzi A; Montillo M; Smolej L; Schuh A; Eyre TA; Kennedy B; Bowles KM; Vignetti M; de la Serna J; Moreno C; Foà R; Ghia P;
Haematologica; 2018 Jul; 103(7):1209-1217. PubMed ID: 29674504
[TBL] [Abstract][Full Text] [Related]
14. Chronic Lymphocytic Leukemia Patients With Deletion 11q Have a Short Time to Requirement of First-Line Therapy, But Long Overall Survival: Results of a Population-Based Cohort in British Columbia, Canada.
Goy J; Gillan TL; Bruyere H; Huang SJT; Hrynchak M; Karsan A; Ramadan K; Connors J; Toze CL; Gerrie AS
Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):382-389. PubMed ID: 28559149
[TBL] [Abstract][Full Text] [Related]
15. Bendamustin-Rituximab Combination Is a Safe and Effective, Ambulatory Treatment for Elderly Patients with Chronic Lymphocytic Leukemia: Retrospective Real-world Analysis by Age from a German Registry and Review of the Literature.
Kleeberg UR; Linde H; Günther G; Tessen HW; Kersting M
Anticancer Res; 2016 Jun; 36(6):2827-38. PubMed ID: 27272794
[TBL] [Abstract][Full Text] [Related]
16. Risk-adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients.
Mattsson A; Sylvan SE; Asklid A; Wiggh J; Winqvist M; Lundin J; Mansouri L; Rosenquist R; Johansson H; Österborg A; Hansson L
Br J Haematol; 2020 Nov; 191(3):426-432. PubMed ID: 32779190
[TBL] [Abstract][Full Text] [Related]
17. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.
Hallek M; Fischer K; Fingerle-Rowson G; Fink AM; Busch R; Mayer J; Hensel M; Hopfinger G; Hess G; von Grünhagen U; Bergmann M; Catalano J; Zinzani PL; Caligaris-Cappio F; Seymour JF; Berrebi A; Jäger U; Cazin B; Trneny M; Westermann A; Wendtner CM; Eichhorst BF; Staib P; Bühler A; Winkler D; Zenz T; Böttcher S; Ritgen M; Mendila M; Kneba M; Döhner H; Stilgenbauer S; ;
Lancet; 2010 Oct; 376(9747):1164-74. PubMed ID: 20888994
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia.
Kay NE; Strati P; LaPlant BR; Leis JF; Nikcevich D; Call TG; Pettinger AM; Lesnick CE; Hanson CA; Shanafelt TD
Oncotarget; 2016 Nov; 7(48):78269-78280. PubMed ID: 27861157
[TBL] [Abstract][Full Text] [Related]
19. First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study.
Meunier G; Ysebaert L; Nguyen-Thi PL; Lepretre S; Quinquenel A; Dupuis J; Lemal R; Aurran T; Tomowiak C; Cymbalista F; Dilhuydy MS; Brion A; Morel P; Cazin B; Leblond V; Cartron G; Ré D; Béné MC; Michallet AS; Feugier P
Hematol Oncol; 2017 Dec; 35(4):671-678. PubMed ID: 27878835
[TBL] [Abstract][Full Text] [Related]
20. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia.
Del Poeta G; Del Principe MI; Consalvo MA; Maurillo L; Buccisano F; Venditti A; Mazzone C; Bruno A; Gianní L; Capelli G; Lo Coco F; Cantonetti M; Gattei V; Amadori S
Cancer; 2005 Dec; 104(12):2743-52. PubMed ID: 16284990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
